Metastatic collecting ducts carcinoma is biologically poorly characterised and under-represented in prospective randomised trials.

The symposium featured three talks and a live Q&A session. First, the current patient journey and standards of care in oesophageal cancer…

Opening the session, Calvo presented a compelling and balanced case about the potential that Phase 0 (Ph0) trials hold for increasing…

Colorectal cancer (CRC) is the second most common cause of cancer-related death in the USA. Despite improvements in screening rates and in the overall survival (OS) of patients with localised and advanced disease over the past few decades, the 5-year OS of patients with metastatic disease is still extremely poor and estimated to be approximately 15%.

Colorectal cancer (CRC) is the third most common cancer in Québec, Canada…

The liver is the most common site for colorectal cancer (CRC) metastases, accounting for 80% of patients with Stage IV CRC and 40% as the only site of distant disease. Of the patients with CRC, 20–25% present with synchronous metastases and 50–60% will develop metachronous disease. Liver metastases develop in the absence of lymph node involvement and, presumably, this occurs via the haematogenous route (the portal circulation) in gastrointestinal tumours from where tumour cells can embolise via the mesenteric veins.

In this study, the serologic status and safety of the SARS-CoV-2 BNT162b2 vaccine in a cohort of patients with solid tumors is evaluated

Pancreatic cancer is the eleventh most commonly diagnosed cancer worldwide and is the seventh leading cause of cancer-related death. It can arise from both exocrine (95%) and endocrine portion (5%) of the pancreatic gland. The most common histology is ductal adenocarcinoma of the pancreas, which accounts for around 80% of all pancreatic cancers, while 65% of the cases arise in the pancreatic head, 15% in the body or tail, and 20% involve the gland diffusely.

Radioresistance is known to create complications in the treatment of cancer.1 Radiation-induced altered adaptive responses by tumour cells or tissues are considered to be primary reasons behind the failure of radiotherapy.2 Acquirement of radioresistance followed by treatment failure and locoregional recurrence is a multifaceted process. Emerging data have suggested various molecular biomarkers necessitate radioresistance in cancer.

Soft tissue sarcomas (STS) are a group of rare mesenchymal tumours that can arise in patients of any age and in a variety of anatomic sites. It is estimated that STS make up 1% of all adult malignancies and that their incidence is on the rise. The lower limb is the most commonly affected site, with approximately 28% of STS arising there. With at least 50 different histologic subtypes, STS are considered highly heterogenous in terms of their histopathology and their tendency to metastasise. Undifferentiated pleomorphic sarcomas and liposarcomas are the most common histopathologic subtypes in adult patients.